Shattuck Labs, Inc. (STTK) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 21, 2023, discloses initial topline dose-expansion data from the Phase 1A/B clinical trial of Shattuck Labs' investigational drug SL-172154. The data covers patients with frontline high-risk myelodysplastic syndromes (HR-MDS) and TP53-mutated acute myeloid leukemia (TP53m AML). The company is an emerging growth company incorporated in Delaware.
Key Clinical Metrics and Financial Status
Clinical Efficacy (Phase 1B - Frontline Patients):
- HR-MDS Cohort: In 14 evaluable patients (13 with TP53m or deletion), 5 achieved Complete Response (CR), 4 achieved morphologic Complete Response (mCR), and 2 achieved Stable Disease (SD) with hematologic improvement.
- TP53m AML Cohort: In 11 evaluable patients, 2 achieved CR, 1 achieved CRi (proceeding to transplant), and 7 had SD with blast reductions. One subject died during the first cycle.
- Activity Signals: Rapid blast count reductions were observed in 100% of frontline TP53m AML patients who received an on-treatment bone marrow biopsy.
Clinical Efficacy (Phase 1A - R/R and Frontline):
- R/R AML: Monotherapy response observed in a heavily pretreated patient who achieved Morphologic Leukemia-Free State (MLFS) and proceeded to transplant.
- Frontline TP53m HR-MDS: In 4 evaluable patients, 1 achieved CR and 1 achieved mCR.
Safety Profile:
- Infusion-related reactions (IRRs) were the most common adverse events (50% in TP53m AML; 32% in HR-MDS).
- Grade 3 or 4 adverse events occurred in 14% of TP53m AML patients and 18% of HR-MDS patients.
- One Grade 5 adverse event (cardiac arrest) was reported in the TP53m AML cohort in a patient with significant pre-existing cardiac history.
- No destructive anemia was observed.
Financial Metrics: The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on clinical trial updates.
Material Changes and Trial Progress
Initial enrollment for the frontline cohorts was completed in the fourth quarter of 2023. Shattuck Labs has elected to expand these cohorts, with additional data expected in mid-2024. The data cut-off dates were December 1, 2023, for the Phase 1B frontline cohorts and September 15, 2023, for the Phase 1A cohorts.
Outlook, Risks, and Management Commentary
Management highlights early efficacy and an acceptable safety profile for SL-172154 in combination with azacitidine (AZA). The company anticipates further data releases in mid-2024. The filing includes standard forward-looking statement disclaimers regarding clinical trial outcomes, regulatory approvals, and capital resources. Risks cited include the unpredictability of clinical results, liquidity constraints, and global macroeconomic conditions.
Key Facts for Investor Verification
- Verify the total number of patients enrolled in the expanded cohorts versus the initial 14 (HR-MDS) and 11 (TP53m AML) evaluable patients.
- Confirm the company's current cash runway and liquidity position, as this filing does not disclose financial status.
- Monitor the mid-2024 data release for confirmation of the initial response rates and long-term durability of responses.
- Review the specific details of the Grade 5 cardiac arrest event to assess potential safety signals for future trials.
- Check for any updates on regulatory interactions or plans for Phase 2 trial initiation.